Karius Announces Data Presentations And Informational Session At ASM Microbe 2017

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius, Inc., a life sciences company focused on conquering infectious diseases, today announced that new data on the company’s next-generation sequencing test will be presented at the American Society for Microbiology’s Microbe 2017 conference taking place at the Ernest N. Morial Convention Center June 1 – 5 in New Orleans.

Abstracts from four studies of the Karius Digital Culture™ test will be presented:

• Detection of Nocardia Cyriacigeorgica from a Deep Pulmonary Infection Using a Novel Plasma-Based Next Generation Sequencing Assay
  presented by Monica Nayakwadi-Singer, M.D., University of California-San Francisco (UCSF) Benioff Children's Hospital Oakland, on June 3 at 12:15 p.m. CT in Exhibit Hall D
• Liquid Biopsy for Infectious Diseases: Application of a Next-Generation Sequencing Cell-Free Plasma Assay to Detect Invasive Fungal Infections
  presented by David Hong, M.D., medical director, Karius, Inc., on June 3 at 4:30 p.m. CT in room 207
• The SEP-SEQ Trial - A Pilot Study Characterizing the Performance of a Novel Plasma Next-Generation Sequencing Assay to Detect Cell-Free Microbial DNA in Patients with Sepsis
  presented by Simone Thair, Ph.D., Stanford University Medical Center, on June 4 at 12:15 p.m. CT in Exhibit Hall D
• The DISCOVER Trial: Application of a Novel Plasma Next-Generation Sequencing Assay to Detect Cell-Free Microbial DNA in Stem-Cell Transplant Patients
  presented by Monica Fung, M.D., UCSF, on June 4 at 12:15 p.m. CT in Exhibit Hall D

Karius will also be presenting “Beyond the Panel,” an informational session highlighting the company’s technology platform and how it has been used by physicians to detect a variety of difficult-to-diagnose pathogens. The presentation will take place Saturday, June 3 at 1:30 p.m. CT in the Industry and Science Showcase Theater A.

About the Karius Digital Culture™ Test

The Karius Digital Culture™ test applies advanced sequencing and analytics for the broad and rapid detection of microbial cell-free DNA through a standard blood draw. Unlike conventional culture and panel testing methods that test for a narrow range of pathogens, the Karius test can detect more than 1,250 pathogens. Through Karius’ CAP-accredited and CLIA-certified laboratory service, the test empowers doctors to diagnose infections, provide more targeted treatment, and spare patients the pain and risks of invasive biopsies.

About Karius, Inc.

Karius is a life sciences company focused on conquering infectious diseases through the innovative use of next-generation sequencing to analyze microbial cell-free DNA. The company’s genomics platform delivers unprecedented insight into the microbial landscape, providing clinicians with a comprehensive test capable of identifying more than a thousand pathogens directly from blood and helping industry accelerate drug development. For more information visit kariusdx.com and follow us on Twitter at @kariusdx.